181 related articles for article (PubMed ID: 27561345)
1. [Teriparatide:benefit and safety for bone disease in CKD patients undergoing hemodialysis].
Yamamoto S; Ei I; Narita I
Clin Calcium; 2016 Sep; 26(9):1301-7. PubMed ID: 27561345
[TBL] [Abstract][Full Text] [Related]
2. Safety and effectiveness of daily teriparatide for osteoporosis in patients with severe stages of chronic kidney disease: post hoc analysis of a postmarketing observational study.
Nishikawa A; Yoshiki F; Taketsuna M; Kajimoto K; Enomoto H
Clin Interv Aging; 2016; 11():1653-1659. PubMed ID: 27895472
[TBL] [Abstract][Full Text] [Related]
3. Teriparatide and bone turnover and formation in a hemodialysis patient with low-turnover bone disease: a case report.
Palcu P; Dion N; Ste-Marie LG; Goltzman D; Radziunas I; Miller PD; Jamal SA
Am J Kidney Dis; 2015 Jun; 65(6):933-6. PubMed ID: 25843705
[TBL] [Abstract][Full Text] [Related]
4. Impact of Weekly Teriparatide on the Bone and Mineral Metabolism in Hemodialysis Patients With Relatively Low Serum Parathyroid Hormone: A Pilot Study.
Yamamoto J; Nakazawa D; Nishio S; Ishikawa Y; Makita M; Kusunoki Y; Nagai S; Fujieda Y; Takahata M; Yamada K; Yamamura T; Yotsukura A; Saito M; Shimazaki M; Atsumi T
Ther Apher Dial; 2020 Apr; 24(2):146-153. PubMed ID: 31210004
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Hemodialysis-Associated Adynamic Bone Disease with Teriparatide (PTH1-34): A Pilot Study.
Cejka D; Kodras K; Bader T; Haas M
Kidney Blood Press Res; 2010; 33(3):221-6. PubMed ID: 20588059
[TBL] [Abstract][Full Text] [Related]
6. [Daily subcutaneous injection of teriparatide : the progress and current issues].
Yano S; Sugimoto T
Clin Calcium; 2014 Jan; 24(1):35-43. PubMed ID: 24369278
[TBL] [Abstract][Full Text] [Related]
7. [The Importance of teriparatide in the treatment of osteoporosis].
Yamauchi M
Clin Calcium; 2016 Jun; 26(6):905-13. PubMed ID: 27230847
[TBL] [Abstract][Full Text] [Related]
8. Therapy for patients with CKD and low bone mineral density.
Ott SM
Nat Rev Nephrol; 2013 Nov; 9(11):681-92. PubMed ID: 24100401
[TBL] [Abstract][Full Text] [Related]
9. [Updates on Lifestyle-Related Diseases and Bone Metabolism. Teriparatide for osteoporosis associated with lifestyle-related diseases].
Fukumoto S
Clin Calcium; 2014 Nov; 24(11):1701-5. PubMed ID: 25355155
[TBL] [Abstract][Full Text] [Related]
10. Treatment of osteoporosis with parathyroid hormone and teriparatide.
Pleiner-Duxneuner J; Zwettler E; Paschalis E; Roschger P; Nell-Duxneuner V; Klaushofer K
Calcif Tissue Int; 2009 Mar; 84(3):159-70. PubMed ID: 19189037
[TBL] [Abstract][Full Text] [Related]
11. [The treatment of the patient presenting with chronic kidney disease (CKD) and fragility fractures].
Giusti A; Fusaro M
G Ital Nefrol; 2017 Dec; 34(Nov-Dec):. PubMed ID: 29207226
[TBL] [Abstract][Full Text] [Related]
12. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.
Brixen KT; Christensen PM; Ejersted C; Langdahl BL
Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):260-70. PubMed ID: 15228497
[TBL] [Abstract][Full Text] [Related]
13. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
[TBL] [Abstract][Full Text] [Related]
14. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.
Nakamura T; Sugimoto T; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Yoshikawa H; Nishizawa Y; Fujita T; Shiraki M
J Clin Endocrinol Metab; 2012 Sep; 97(9):3097-106. PubMed ID: 22723322
[TBL] [Abstract][Full Text] [Related]
15. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of osteoporosis with PTH].
Takeuchi Y
Clin Calcium; 2014 Jun; 24(6):893-902. PubMed ID: 24870841
[TBL] [Abstract][Full Text] [Related]
17. [Effects of parathyroid hormone (teriparatide) on bone mass and quality in osteoporosis].
Marumo K; Saito M
Nihon Rinsho; 2011 Jul; 69(7):1264-9. PubMed ID: 21774369
[TBL] [Abstract][Full Text] [Related]
18. Impact of long-term cinacalcet, ibandronate or teriparatide therapy on bone mineral density of hemodialysis patients: a pilot study.
Mitsopoulos E; Ginikopoulou E; Economidou D; Zanos S; Pateinakis P; Minasidis E; Memmos D; Thodis E; Vargemezis V; Tsakiris D
Am J Nephrol; 2012; 36(3):238-44. PubMed ID: 22948280
[TBL] [Abstract][Full Text] [Related]
19. Anabolic therapies for osteoporosis.
Uihlein AV; Leder BZ
Endocrinol Metab Clin North Am; 2012 Sep; 41(3):507-25. PubMed ID: 22877427
[TBL] [Abstract][Full Text] [Related]
20. Anabolic therapy for osteoporosis.
Bilezikian JP
Int J Fertil Womens Med; 2005; 50(2):53-60. PubMed ID: 16334411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
